Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAT2A | P31153 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10153088 | 0.77 | SORD (0.41) | SMN1; SMN2DPP4ALDH1A1PDCD1CD274 | |
| SCHEMBL10153133 | 0.76 | ALDH1A1 (0.48) | SMN1; SMN2DPP4ALDH1A1KDM4EMAPT | |
| SCHEMBL1083616 | 0.74 | ALDH1A1 (0.47) | SMN1; SMN2DPP4ALDH1A1KDM4EMAPT | |
| SCHEMBL540845 | 0.74 | MAPK1 (0.59) | SMN1; SMN2DPP4ALDH1A1KDM4EMAPT | |
| SCHEMBL20033206 | 0.74 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1PDCD1CD274KDM4E | |
| Lithium Ion SCHEMBL1083615 | 0.73 | HTR2A (0.45) | SMN1; SMN2DPP4ALDH1A1KDM4EMAPT | |
| SCHEMBL30436933 | 0.72 | SMN1; SMN2 (0.53) | SMN1; SMN2DPP4ALDH1A1PDCD1CD274 | |
| SCHEMBL4675341 | 0.72 | SMN1; SMN2 (0.53) | SMN1; SMN2DPP4ALDH1A1PDCD1CD274 | |
| SCHEMBL7588836 | 0.71 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1PDCD1CD274KDM4E | |
| SCHEMBL1077879 | 0.70 | HPGD (0.50) | SMN1; SMN2ALDH1A1KDM4EMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938259-B2 | Therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170283401-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9657004-B2 | Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC (US) | 2017-05-23 | — | — | US | disclosed |
| US-9181231-B2 | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia | AGIOS PHARMACEUTICALS, INC (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140323729-A1 | PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140179694-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | AGIOS PHARMACEUTICALS, INC (US) | 2014-06-26 | — | — | US | disclosed |
| US-8742119-B2 | Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20120122885-A1 | PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323729-A1 | PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | PDK2, PDK1, PDK3 | SMN1; SMN2 4384/4885DPP4 707/4885ALDH1A1 1387/4885 |
| US-20170283401-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | PDK2, PDK1, PDK3 | SMN1; SMN2 3566/4885DPP4 841/4885ALDH1A1 1240/4885 |
| US-20140179694-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | PCK1, PDK2, PFKP | SMN1; SMN2 3273/4885DPP4 1083/4885ALDH1A1 1010/4885 |
| US-20120122885-A1 | PYRUVATE KINASE M2 MODULATORS, THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | PDK2, PDK1, PDK3 | SMN1; SMN2 4384/4885DPP4 707/4885ALDH1A1 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.